W. Mark Watson Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for W. Mark Watson.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of W. Mark Watson. W. Mark Watson is Director in SYKES ENTERPRISES INC ($SYKE) and Director in HedgePath Pharmaceuticals, Inc. ($HPPI) and Director in BIODELIVERY SCIENCES INTERNATIONAL INC ($BDSI).
Latest Insider Trading Transactions of W. Mark Watson
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, BDSI, HPPI, SYKE
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 22 2021 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 41.93 | 181 | 7,589 | 10,715 | 10.5 K to 10.7 K (+1.72 %) |
| Feb 16 2021 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 42.86 | 1,000 | 42,860 | 10,534 | 9.5 K to 10.5 K (+10.49 %) |
| Dec 28 2020 | HPPI | Inhibitor Therapeu ... | Watson W. Mark | Director | Option Exercise | A | 0.03 | 1,306,452 | 40,500 | 1,306,452 | |
| Nov 13 2020 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 37.20 | 1,000 | 37,200 | 9,353 | 8.4 K to 9.4 K (+11.97 %) |
| Aug 24 2020 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 33.42 | 181 | 6,049 | 8,353 | 8.2 K to 8.4 K (+2.21 %) |
| Aug 19 2020 | BDSI | BIODELIVERY SCIENC ... | Watson W. Mark | Director | Sell | S | 5.18 | 13,000 | 67,340 | 52,979 | 66 K to 53 K (-19.70 %) |
| Aug 13 2020 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 34.36 | 1,000 | 34,360 | 8,172 | 7.2 K to 8.2 K (+13.94 %) |
| Aug 11 2020 | BDSI | BIODELIVERY SCIENC ... | Watson W. Mark | Director | Option Exercise | M | 0.00 | 30,000 | 0 | 45,000 | |
| Aug 11 2020 | BDSI | BIODELIVERY SCIENC ... | Watson W. Mark | Director | Option Exercise | M | 0.00 | 30,000 | 0 | 45,000 | |
| Aug 11 2020 | BDSI | BIODELIVERY SCIENC ... | Watson W. Mark | Director | Buy | M | 0.00 | 30,000 | 0 | 65,979 | 36 K to 66 K (+83.38 %) |
| Aug 11 2020 | BDSI | BIODELIVERY SCIENC ... | Watson W. Mark | Director | Buy | M | 0.00 | 30,000 | 0 | 65,979 | 36 K to 66 K (+83.38 %) |
| May 22 2020 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 25.95 | 181 | 4,697 | 7,172 | 7 K to 7.2 K (+2.59 %) |
| May 13 2020 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 25.00 | 1,000 | 25,000 | 6,991 | 6 K to 7 K (+16.69 %) |
| Mar 30 2020 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Sell | S | 26.10 | 3,000 | 78,300 | 5,991 | 9 K to 6 K (-33.37 %) |
| Mar 24 2020 | HPPI | Inhibitor Therapeu ... | Watson W. Mark | Director | Option Exercise | A | 0.05 | 1,500,000 | 75,000 | 1,500,000 | |
| Feb 24 2020 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 35.67 | 181 | 6,456 | 8,991 | 8.8 K to 9 K (+2.05 %) |
| Feb 21 2020 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 35.95 | 983 | 35,339 | 8,810 | 7.8 K to 8.8 K (+12.56 %) |
| Nov 22 2019 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 34.92 | 181 | 6,321 | 7,827 | 7.6 K to 7.8 K (+2.37 %) |
| Nov 21 2019 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 35.27 | 984 | 34,706 | 7,646 | 6.7 K to 7.6 K (+14.77 %) |
| Aug 22 2019 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 29.19 | 181 | 5,283 | 6,662 | 6.5 K to 6.7 K (+2.79 %) |
| Aug 21 2019 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 28.89 | 984 | 28,428 | 6,481 | 5.5 K to 6.5 K (+17.90 %) |
| Aug 15 2019 | BDSI | BIODELIVERY SCIENC ... | Watson W. Mark | Director | Option Exercise | M | 0.00 | 24,739 | 0 | 74,640 | |
| Aug 15 2019 | BDSI | BIODELIVERY SCIENC ... | Watson W. Mark | Director | Buy | M | 0.00 | 24,739 | 0 | 35,979 | 11.2 K to 36 K (+220.10 %) |
| Jun 10 2019 | HPPI | HedgePath Pharmace ... | Watson W. Mark | Director | Option Exercise | A | 0.07 | 25,000 | 1,825 | 25,000 | |
| May 22 2019 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 25.75 | 180 | 4,635 | 5,497 | 5.3 K to 5.5 K (+3.39 %) |
| May 21 2019 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 25.41 | 984 | 25,003 | 5,317 | 4.3 K to 5.3 K (+22.71 %) |
| Feb 25 2019 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 31.10 | 904 | 28,114 | 4,333 | 3.4 K to 4.3 K (+26.36 %) |
| Feb 22 2019 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 30.51 | 180 | 5,492 | 3,429 | 3.2 K to 3.4 K (+5.54 %) |
| Feb 05 2019 | HPPI | HedgePath Pharmace ... | Watson W. Mark | Director | Option Exercise | A | 0.08 | 657,895 | 50,000 | 657,895 | |
| Nov 26 2018 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 26.82 | 903 | 24,218 | 3,249 | 2.3 K to 3.2 K (+38.49 %) |
| Nov 26 2018 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 26.82 | 180 | 4,828 | 2,346 | 2.2 K to 2.3 K (+8.31 %) |
| Aug 23 2018 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 29.31 | 903 | 26,467 | 2,166 | 1.3 K to 2.2 K (+71.50 %) |
| Aug 23 2018 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 29.31 | 903 | 26,467 | 2,166 | 1.3 K to 2.2 K (+71.50 %) |
| Aug 22 2018 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 29.42 | 180 | 5,296 | 1,263 | 1.1 K to 1.3 K (+16.62 %) |
| Aug 16 2018 | BDSI | BIODELIVERY SCIENC ... | Watson W. Mark | Director | Option Exercise | M | 0.00 | 9,740 | 0 | 99,379 | |
| Aug 16 2018 | BDSI | BIODELIVERY SCIENC ... | Watson W. Mark | Director | Buy | M | 0.00 | 9,740 | 0 | 11,240 | 1.5 K to 11.2 K (+649.33 %) |
| Aug 03 2018 | BDSI | BIODELIVERY SCIENC ... | Watson W. Mark | Director | Option Exercise | A | 2.93 | 54,770 | 160,476 | 54,770 | |
| Aug 03 2018 | BDSI | BIODELIVERY SCIENC ... | Watson W. Mark | Director | Option Exercise | A | 0.00 | 109,479 | 0 | 109,479 | |
| May 30 2018 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 27.68 | 903 | 24,995 | 1,083 | 180 to 1.1 K (+501.67 %) |
| May 25 2018 | SYKE | SYKES ENTERPRISES ... | Watson W. Mark | Director | Grant | A | 27.69 | 180 | 4,984 | 180 | 0 to 180 |
| Mar 15 2018 | HPPI | HedgePath Pharmace ... | Watson W. Mark | Director | Option Exercise | A | 0.27 | 76,000 | 20,687 | 76,000 | |
| Mar 15 2018 | HPPI | HedgePath Pharmace ... | Watson W. Mark | Director | Option Exercise | A | 0.27 | 253,000 | 68,867 | 253,000 | |
| Mar 10 2017 | HPPI | HedgePath Pharmace ... | Watson W. Mark | Director | Option Exercise | M | 0.00 | 200,000 | 0 | 0 | |
| Mar 10 2017 | HPPI | HedgePath Pharmace ... | Watson W. Mark | Director | Option Exercise | M | 0.00 | 400,000 | 0 | 0 | |
| Mar 10 2017 | HPPI | HedgePath Pharmace ... | Watson W. Mark | Director | Option Exercise | M | 0.00 | 300,000 | 0 | 0 | |
| Mar 10 2017 | HPPI | HedgePath Pharmace ... | Watson W. Mark | Director | Payment of Exercise | F | 0.34 | 79,200 | 26,928 | 553,600 | 632.8 K to 553.6 K (-12.52 %) |
| Mar 10 2017 | HPPI | HedgePath Pharmace ... | Watson W. Mark | Director | Buy | M | 0.00 | 200,000 | 0 | 632,800 | 432.8 K to 632.8 K (+46.21 %) |
| Mar 10 2017 | HPPI | HedgePath Pharmace ... | Watson W. Mark | Director | Payment of Exercise | F | 0.34 | 158,400 | 53,856 | 432,800 | 591.2 K to 432.8 K (-26.79 %) |
| Mar 10 2017 | HPPI | HedgePath Pharmace ... | Watson W. Mark | Director | Buy | M | 0.00 | 400,000 | 0 | 591,200 | 191.2 K to 591.2 K (+209.21 %) |
| Mar 10 2017 | HPPI | HedgePath Pharmace ... | Watson W. Mark | Director | Payment of Exercise | F | 0.34 | 118,800 | 40,392 | 191,200 | 310 K to 191.2 K (-38.32 %) |
| Mar 10 2017 | HPPI | HedgePath Pharmace ... | Watson W. Mark | Director | Buy | M | 0.00 | 300,000 | 0 | 310,000 | 10 K to 310 K (+3,000.00 %) |
| Jul 06 2016 | HPPI | HedgePath Pharmace ... | Watson W. Mark | Director | Option Exercise | A | 0.24 | 200,000 | 48,000 | 200,000 | |
| Jul 06 2016 | HPPI | HedgePath Pharmace ... | Watson W. Mark | Director | Option Exercise | A | 0.00 | 200,000 | 0 | 200,000 | |
| Aug 18 2015 | HPPI | HedgePath Pharmace ... | Watson W. Mark | Director | Option Exercise | A | 0.00 | 400,000 | 0 | 400,000 |
Page: 1